Sanofi TheraCys Shortage Prompts Merck To “More Than Double” Supply Of TICE BCG
11:53 EDT 11 Jul 2012 | Elsevier Business Intelligence
In its latest attempt to get out in front of drug shortage problems, FDA’s announcement that Sanofi Pasteur’s bladder cancer drug TheraCys is unavailable due to manufacturing problems also notifies patients that Merck is stepping into the breach
Original Article: Sanofi TheraCys Shortage Prompts Merck To “More Than Double” Supply Of TICE BCG
More From BioPortfolio on "Sanofi TheraCys Shortage Prompts Merck To “More Than Double” Supply Of TICE BCG"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
